Asthma Clinical Trial
Official title:
The Effects of HOST-DM059 Prebiotic Supplementation on Gut Bacterial Metabolites, and Markers of Systemic Inflammation in Adults With and Without Hyperpnoea-Induced Bronchoconstriction: A Double-Blind, Placebo-Controlled, Crossover Trial.
The current study aims to explore the role of prebiotic supplementation in adults with and without Asthma/Exercise-Induced Bronchoconstriction (A/EIB). All participants will be asked to consume a prebiotic supplement, and a placebo, each for a total duration of four weeks, separated by a two-week wash out period. The investigators hypothesise that improvements in pulmonary function observed in adults with Asthma following prebiotic supplementation. We hypothesise that improvements in pulmonary function will be attributed, at least in part, to gut microbiota mediated improvements in human immune function.
The current study will investigate the effects of prebiotic supplementation on airway
inflammation/bronchoconstriction in adults diagnosed with Asthma/Exercise-Induced
Bronchoconstriction (A/EIB). Previous research conducted in adults diagnosed with A/EIB has
reported significant improvements in pulmonary function following three weeks of prebiotic
supplementation. The significant improvements in pulmonary function were attributed to an
attenuation of various markers of airway inflammation, potentially regulated by gut
microbiota mediated improvements in systemic immune function.
Prebiotics are a type of non-digestible carbohydrate/dietary fibre that can only be digested
by certain beneficial bacteria. During the fermentation of prebiotics, beneficial bacteria
produce energy/metabolites that can be used to support a variety of human immune functions,
such as reducing the level of airway inflammation that occurs following exposure to relevant
triggers (e.g. exercise).
Imbalances and/or deficiencies in gut bacterial composition/metabolic activity have been
identified in children/adults diagnosed asthma. However, the potential mechanisms behind
prebiotic mediated improvements in the severity of asthma have yet to be investigated.
Participants with and without A/EIB will be allocated two separate nutritional supplements
following a double-blind, placebo-controlled design. During the first phase of the
nutritional intervention, participants will consume the first supplement (either prebiotic or
placebo), for a total duration of four weeks. A two-week wash out period will then be
completed before the remaining nutritional supplement is administered for an equal duration.
Analyses of key human/bacterial metabolite concentrations will be carried out alongside
assessments of immune and pulmonary function, and intestinal permeability at baseline, and
throughout all phases of the nutritional intervention. Current understandings of the role of
the gut microbiota in the pathogenesis of A/EIB will be expanded through the investigation of
novel pathophysiological mechanisms, helping to inform future therapeutic prospects for
asthma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|